VASCOR Drug Patent Profile

Which patents cover Vascor, and when can generic versions of Vascor launch?

Vascor is a drug marketed by Johnson And Johnson and Mallinckrodt and is included in two NDAs.

The generic ingredient in VASCOR is iothalamate meglumine; iothalamate sodium. There is one drug master file entry for this compound. Additional details are available on the iothalamate meglumine; iothalamate sodium profile page.

Summary for VASCOR

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for VASCOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-001	Dec 28, 1990		DISCN	No	No
Mallinckrodt	VASCORAY	iothalamate meglumine; iothalamate sodium	INJECTABLE;INJECTION	016783-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-002	Dec 28, 1990		DISCN	No	No
Johnson And Johnson	VASCOR	bepridil hydrochloride	TABLET;ORAL	019002-003	Dec 28, 1990		DISCN	No	No

International Patents for VASCOR

See the table below for patents covering VASCOR around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	795735
Canada	1015360	ETHYLENEDIAMINES SUBSTITUEES A ACTIVITE CARDIOVASCULAIRE
Canada	1048027	ETHYLENEDIAMINES SUBSTITUEES A ACTIVITE CARDIOVASCULAIRE (SUBSTITUTED ETHYLENE DIAMINE WITH CARDIOVASCULAR ACTIVITIES)
Switzerland	556815	PROCEDE POUR LA PREPARATION DES PROPYLAMINES.
Germany	2310918
Spain	412203

Last updated: July 14, 2026

VASCOR investment scenario and patent fundamentals analysis (IP, FDA status, and generic risk)

No reliable, specific public record set for “VASCOR” (drug name, active ingredient, NDA/BLA number, FDA approval date, Orange Book listings, or litigation/settlement history) is available in the provided context. Without the active ingredient and FDA identifier, a complete patent-and-exclusivity fundamentals analysis would be inaccurate.

What is VASCOR (active ingredient, indication, and FDA approval basics)?

No data is provided that identifies the active ingredient, route of administration, strength, dosage form, or the FDA application type (NDA vs ANDA vs BLA), so fundamentals cannot be tied to a real patent estate or FDA exclusivity clock.

Which regulatory identifiers define VASCOR (NDA, Orange Book listing, RLD)?

No NDA/BLA number, Orange Book code, RLD name, applicant/holder, or labeling revision dates are provided, so the Orange Book status cannot be mapped to specific patents and exclusivity.

What patents protect VASCOR and how many are in the estate?

No patent numbers, assignees, jurisdictions, or claims scope are provided, so patent coverage, count by category (composition, formulation, method of use, device, manufacturing), and anticipated expiration cannot be calculated.

How do composition-of-matter patents vs formulation patents differ for VASCOR?

No VASCOR-specific patent set is available to classify claims by category.

What method-of-use patents cover VASCOR dosing or patient populations?

No indication, labeled dosing, or VASCOR-specific method claims are provided.

Which jurisdictions matter for enforcement: US, EP, JP, CN?

No filing strategy or family information is provided.

When does VASCOR lose exclusivity (patent term vs regulatory exclusivity)?

No FDA exclusivity start dates, patent expiration dates, pediatric exclusivity, REMS ties, or orphan status information is provided, so exclusivity timelines cannot be produced.

What is the Orange Book status of VASCOR?

No Orange Book listing is provided, so the patent/information table cannot be summarized.

How long is VASCOR protected by exclusivity under Hatch-Waxman?

No NDA type, approval history, or exclusivity determinations are provided.

What generic entry risks exist for VASCOR (ANDAs, Paragraph IV, 505(b)(2))?

No ANDA filing history, Paragraph IV notices, or litigation documents are provided, so the generic attack risk cannot be quantified.

Which companies are challenging VASCOR with Paragraph IV certifications?

No challengers are provided.

How strong is the patent estate for VASCOR against generics?

No claim-by-claim construction or typical infringement/invalidity posture is available without patent numbers and litigation status.

What VASCOR patent litigation affects investors (cases, settlements, deadlines)?

No litigation docket numbers, court venues, stay dates, settlement triggers, or final judgments are provided.

What settlement agreements control generic launch timing for VASCOR?

No settlement terms are provided.

What are the key court dates and appeal risk for VASCOR?

No case timeline is provided.

How does VASCOR compare with competing drugs in the same therapeutic class (pricing and market exposure)?

No therapeutic class, competitor set, or market access context is provided, so competitive positioning and revenue exposure cannot be grounded.

Which branded alternatives and biosimilars compete with VASCOR?

No competitors are provided.

What is the revenue exposure for VASCOR from payer formulary pressure?

No sales, net price, or payer outcomes are provided.

What formulations are protected by VASCOR patents (IR/ER, combination products, and delivery system claims)?

No formulation patents or dosage form details are provided.

Is VASCOR protected by process and manufacturing method patents?

No manufacturing/process patents are provided.

What investor signals matter most for VASCOR (pipeline dependencies, label expansions, and lifecycle management)?

No pipeline, label expansion status, post-approval supplements, or additional indications are provided.

Key Takeaways

• A complete investment scenario and patent fundamentals analysis for “VASCOR” cannot be produced without the active ingredient and FDA application identifier.
• No patent estate (composition, formulation, method-of-use), Orange Book listing, exclusivity schedule, or generic/Paragraph IV litigation history can be mapped from the provided information.
• No defensible competitive or revenue exposure assessment can be constructed without therapeutic class, labeled uses, and market data tied to a specific FDA product.

FAQs

1. How do I determine whether “VASCOR” has an Orange Book listing if the active ingredient is unclear?
2. What indicators in Orange Book listings typically predict a tighter generic entry window under Hatch-Waxman?
3. How should investors interpret method-of-use versus formulation patent expirations for branded drugs?
4. What is the typical impact of pediatric exclusivity and REMS on branded drug cash flows?
5. What documentation best supports an assessment of Paragraph IV strength in US generic challenges?

References

No sources were cited because no VASCOR-specific regulatory or patent records were provided.